Lantern Pharma
CompanyUnited States
Lantern Pharma develops one asset, in phase 2 (LP-300 in non-small cell lung cancer). Mostly small molecule acting on Oxidative stress and ROS signalling; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 2
- 1
- Trial
- 0
- Signals
Pipeline
1Modulates cellular redox pathways to enhance tumor sensitivity to chemotherapy.
Phase 2, Small molecule, Oxidative stress and ROS signalling, non-small cell lung cancer
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials2
- Similar companies6